Bristol-Myers Squibb Company (BMY) is a prominent biopharmaceutical company with a focus on treating various diseases. With a market cap of $96.5 billion, its operations span multiple regions globally, including the Americas, Europe, and the Indo-Pacific.

Despite being classified as a large-cap stock, BMY has seen a 25% drop from its two-year high. Over the past three months, its stock prices have lagged behind the iShares U.S. Pharmaceuticals ETF, dipping 1.2%.

Long-term trends show BMY stock prices have fallen 16% YTD and nearly 6% over the past 52 weeks. This underperformance compared to the market trend is evident, with BMY trading below its 50-day moving average since April.

Following the release of its Q2 results, BMY stock prices plummeted 5.8% despite reporting better-than-expected results. Sales from the legacy portfolio decreased by 14%, but the growth portfolio saw an 18% increase year-over-year.

BMY has lowered its full-year adjusted EPS guidance, leading to a sell-off. Despite this, the company has outperformed its peer, Regeneron Pharmaceuticals, Inc., in terms of stock performance.

Analysts give BMY a consensus rating of “Hold,” with a mean price target of $52.28, representing a 10.1% premium to current levels. This information is meant for informational purposes only.

Read more at Yahoo Finance: How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?